Jesús García-Bañuelos

Dr. Jesús García-Bañuelos

Instituto de Biología Moleculñar en Medicina y Terapia génica, Universidad de Guadalajra, CUCS, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
JGJorge Gutiérrez-Cuevas
Jorge Gutiérrez-Cuevas
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
AMAlejandra Meza-Rios
Alejandra Meza-Rios
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
MGMarina Galicia-Moreno
Marina Galicia-Moreno
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda
Obesity is defined as excessive body fat accumulation, and worldwide obesity has nearly tripled since 1975. Excess of free fatty acids (FFAs) and triglycerides in obese individuals promote ectopic lipid accumulation in the liver, skeletal muscle tissue, and heart, among others, inducing insulin resistance, hypertension, metabolic syndrome, type 2 diabetes (T2D), atherosclerosis, and cardiovascular disease (CVD). These diseases are promoted by visceral white adipocyte tissue (WAT) dysfunction through an increase in pro-inflammatory adipokines, oxidative stress, activation of the renin-angiotensin-aldosterone system (RAAS), and adverse changes in the gut microbiome. In the heart, obesity and T2D induce changes in substrate utilization, tissue metabolism, oxidative stress, and inflammation, leading to myocardial fibrosis and ultimately cardiac dysfunction. Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of carbohydrate and lipid metabolism, also improve insulin sensitivity, triglyceride levels, inflammation, and oxidative stress. The purpose of this review is to provide an update on the molecular mechanisms involved in obesity-linked CVD pathophysiology, considering pro-inflammatory cytokines, adipokines, and hormones, as well as the role of oxidative stress, inflammation, and PPARs. In addition, cell lines and animal models, biomarkers, gut microbiota dysbiosis, epigenetic modifications, and current therapeutic treatments in CVD associated with obesity are outlined in this paper.

26 January 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
JGJorge Gutiérrez-Cuevas
Jorge Gutiérrez-Cuevas
MGMarina Galicia-Moreno
Marina Galicia-Moreno
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
Jesús García-BañuelosJesús García-Bañuelos
Jesús García-Bañuelos
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda
The raising prevalence of obesity is associated with an increased risk for cardiovascular diseases (CVDs), particularly coronary artery disease (CAD), and heart failure, including atrial fibrillation, ventricular arrhythmias and sudden death. Obesity contributes directly to incident cardiovascular risk factors, including hyperglycemia or diabetes, dyslipidemia, and hypertension, which are involved in atherosclerosis, including structural and functional cardiac alterations, which lead to cardiac dysfunction. CVDs are the main cause of morbidity and mortality worldwide. In obesity, visceral and epicardial adipose tissue generate inflammatory cytokines and reactive oxygen species (ROS), which induce oxidative stress and contribute to the pathogenesis of CVDs. Nuclear factor erythroid 2-related factor 2 (NRF2; encoded by Nfe2l2 gene) protects against oxidative stress and electrophilic stress. NRF2 participates in the regulation of cell inflammatory responses and lipid metabolism, including the expression of over 1000 genes in the cell under normal and stressed environments. NRF2 is downregulated in diabetes, hypertension, and inflammation. Nfe2l2 knockout mice develop structural and functional cardiac alterations, and NRF2 deficiency in macrophages increases atherosclerosis. Given the endothelial and cardiac protective effects of NRF2 in experimental models, its activation using pharmacological or natural products is a promising therapeutic approach for obesity and CVDs. This review provides a comprehensive summary of the current knowledge on the role of NRF2 in obesity-associated cardiovascular risk factors.

21 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JGJorge Gutiérrez-Cuevas
Jorge Gutiérrez-Cuevas
DLDaniel López-Cifuentes
Daniel López-Cifuentes
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
Jesús García-BañuelosJesús García-Bañuelos
Jesús García-Bañuelos
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda
Obesity has increasingly become a worldwide epidemic, as demonstrated by epidemiological and clinical studies. Obesity may lead to the development of a broad spectrum of cardiovascular diseases (CVDs), such as coronary heart disease, hypertension, heart failure, cerebrovascular disease, atrial fibrillation, ventricular arrhythmias, and sudden cardiac death. In addition to hypertension, there are other cardiometabolic risk factors (CRFs) such as visceral adiposity, dyslipidemia, insulin resistance, diabetes, elevated levels of fibrinogen and C-reactive protein, and others, all of which increase the risk of CVD events. The mechanisms involved between obesity and CVD mainly include insulin resistance, oxidative stress, inflammation, and adipokine dysregulation, which cause maladaptive structural and functional alterations of the heart, particularly left-ventricular remodeling and diastolic dysfunction. Natural products of plants provide a diversity of nutrients and different bioactive compounds, including phenolics, flavonoids, terpenoids, carotenoids, anthocyanins, vitamins, minerals, fibers, and others, which possess a wide range of biological activities including antihypertensive, antilipidemic, antidiabetic, and other activities, thus conferring cardiometabolic benefits. In this review, we discuss the main therapeutic interventions using extracts from herbs and plants in preclinical and clinical trials with protective properties targeting CRFs. Molecular mechanisms and therapeutic targets of herb and plant extracts for the prevention and treatment of CRFs are also reviewed.

11 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
CMC. Alejandra Monraz-Méndez
C. Alejandra Monraz-Méndez
RERebeca Escutia-Gutiérrez
Rebeca Escutia-Gutiérrez
JRJonathan Samael Rodriguez-Sanabria
Jonathan Samael Rodriguez-Sanabria
MGMarina Galicia-Moreno
Marina Galicia-Moreno
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
Background and aims. Metabolic Associated Fatty Liver Disease (MAFLD) encompasses a spectrum of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH). Here, we investigated the hepatoprotective role of Moringa oleifera aqueous extract on hepatic miRNAs, genes and protein expression, as well as histological and biochemical parameters in an experimental model of NASH. Methods. Male C57BL/6J mice were fed with a high fat diet (HFD, 60% lipids, 42 gr/L sugar in water) for 16 weeks. Moringa extract was administered via gavage during the final 8 weeks. Insulin Tolerance Test (ITT) and HOMA-IR were calculated. Serum levels of insulin, resistin, leptin and PAI-1 and hepatic expression of miR-21a-5p, miR-103-3p, miR-122-5p, miR-34a-5p and SIRT1, AMPKα and SREBP1c protein were evaluated. Alpha-SMA immunohistochemistry and hematoxylin-eosin, Masson’s trichrome and sirius red staining were made. Hepatic transcriptome was analyzed using microarrays. Results. Animals treated with Moringa extract improved ITT and decreased SREBP1c hepatic protein, while SIRT1 increased. Hepatic expression of miR-21a-5p, miR-103-3p and miR-122-5p, miR34a-5p was downregulated. Hepatic histologic analysis showed in Moringa group (HF + MO) a significant decrease in inflammatory nodules, macro steatosis, fibrosis, collagen and αSMA reactivity. Analysis of hepatic transcriptome showed down expression of mRNAs implicated in DNA response to damage, endoplasmic reticulum stress, lipid biosynthesis and insulin resistance. Moringa reduced insulin resistance, de novo lipogenesis, hepatic inflammation and ER stress. Conclusions. Moringa prevented progression of liver damage in a model of NASH and improved biochemical, histological and hepatic expression of genes and miRNAs implicated in MAFLD/NASH development.

22 October 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
MGMarina Galicia-Moreno
Marina Galicia-Moreno
HMHugo Christian Monroy-Ramirez
Hugo Christian Monroy-Ramirez
FCFernando Caloca-Camarena
Fernando Caloca-Camarena
SAScarlet Arceo-Orozco
Scarlet Arceo-Orozco
PMPablo Muriel
Pablo Muriel
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda

1 March 2020 in Journal of Medicinal Food
Verified
Journal Article
Closed access
AGAngélica S. González-Garibay
Angélica S. González-Garibay
ALAlfonso López-Vázquez
Alfonso López-Vázquez
Jesús García-BañuelosJesús García-Bañuelos
Jesús García-Bañuelos
SSSergio Sánchez-Enríquez
Sergio Sánchez-Enríquez
ASAna S. Sandoval-Rodríguez
Ana S. Sandoval-Rodríguez
BBBlanca E. Bastidas-Ramírez
Blanca E. Bastidas-Ramírez
Excess of visceral adipose tissue (VAT) characteristic of obesity leads to a proinflammatory state disrupting the insulin signaling pathway, triggering insulin resistance (IR) and inflammation, the main processes contributing to obesity comorbidities. Ursolic acid (UA), a pentacyclic triterpenoid occurring in a variety of plant foods, exhibits anti-inflammatory properties. The aim of this study was to evaluate UA effects on IR, hyperinsulinemia, and inflammation in experimental diet-induced obesity. Forty male Wistar rats were randomly assigned to eight groups (n = 5). One group was used for time 0. Three groups were labeled as OBE (control): receiving high-fat diet (HFD; fat content 45.24% of energy) during 3, 6, or 9 weeks; three groups UA-PREV: exposed to simultaneous HFD and UA during 3, 6, or 9 weeks to evaluate UA preventive effects; one group UA-REV: receiving HFD for 6 weeks, followed by simultaneous HFD and UA for three additional weeks to analyze UA reversal effects. Measurements were performed after 3, 6, or 9 weeks of treatment. Adiposity was calculated by weighing VAT after sacrifice. Serum markers were quantified through colorimetric and enzyme-linked immunosorbent assay methods. VAT adipokines RNAm expression was evaluated by quantitative reverse transcriptase–polymerase chain reaction. Data were analyzed by Kruskal–Wallis and Mann–Whitney U tests. UA significantly decreased adiposity, IR, hyperinsulinemia, triacylglycerides, and cholesterol levels, and also VAT mRNA expression of MCP-1 (monocyte chemoattractant protein-1), IL (interleukin)-1β and IL-6, concomitantly increasing adiponectin levels. UA metabolic effects demonstrated in this study support its potential therapeutic utility to improve IR, hyperinsulinemia, and inflammation observed in obesity and diabetes.